https://www.curefipeurope.com/product-page/20mg 2026-06-22 https://static.wixstatic.com/media/0bcfb2_9c1a2449d0394c56a912a7b743c55094~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_c180457ac64b406494a6c591378991a5~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_39758857b3804f63a4f1c9f35513bac2~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_886f657c3aff4365867a44be03c9d326~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_5138059f1367434297930c9175e5299d~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_2def33054646443bb8642d84a0690a16~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_ccf0e83507974af79d5b759e7630ecd7~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4f002.jpg/v1/fit/w_50,h_50,q_90/file.jpg CureFIP™ GS-441524 Injectable 20mg/ml, 10ML CureFIP™ GS-441524 Injectable 20mg/ml Precision Dosing Formulation for Small Cats and Kittens What This Product IsCureFIP™ GS-441524 20mg/ml is the lowest-concentration injectable in our range. It contains the same active antiviral compound — GS-441524 — as our 30mg/ml and 40mg/ml formulations. The total dose of GS-441524 delivered per treatment (measured in mg per kg of body weight) is identical across all three concentrations. Concentration does not determine efficacy. It determines injection volume — and injection volume determines dosing accuracy. Why Concentration Matters for Small CatsFIP treatment dosing is calculated in mg of GS-441524 per kg of body weight. In cats weighing under 2.5 kg, the required dose per injection is small in absolute terms. When that small dose is drawn from a high-concentration formulation, the resulting injection volume becomes extremely small — often below the reliable measurement threshold of standard syringes.A measurement error of 0.05ml in a 0.1ml injection represents a 50% dosing error. In FIP treatment, consistent and accurate dosing across all 84 days of the protocol directly influences treatment outcome. Underdosing extends the time to remission and increases resistance risk. Overdosing creates unnecessary burden on a small cat's physiology.The 20mg/ml format resolves this by producing a clinically manageable injection volume for cats in the under-2.5 kg weight range, where dosing precision matters most. Indicated CasesThis formulation is appropriate for:<ul> <li>Adult cats weighing under 2.5 kg</li> <li>Kittens diagnosed with FIP at any stage</li> <li>Cats that have lost significant weight during illness and now fall below 2.5 kg</li> <li>Cases where the attending veterinarian has specified low-concentration formulation for precision dosing</li></ul> This Formulation Is Not the First Choice For<ul> <li>Cats weighing 2.5 kg or above — the 30mg/ml formulation is more appropriate</li> <li>Cases requiring high-dose induction protocols — the 40mg/ml formulation is indicated</li> <li>Cases presenting with anaemia, neurological involvement, or significant appetite loss — consider the CureFIP™ GS-441524 + B12 20mg/ml formulation, which integrates cobalamin support alongside antiviral treatment</li></ul> Clinical BackgroundGS-441524 is a nucleoside analogue that functions as an RNA-dependent RNA polymerase (RdRp) inhibitor. Following cellular uptake and phosphorylation to its active triphosphate form, it is incorporated into nascent viral RNA chains, causing delayed chain termination and halting feline coronavirus (FCoV/FIPV) replication. The compound was identified as an effective FIP treatment in landmark research published in Nature in 2019 (Pedersen et al.) and has since been evaluated in multiple prospective and retrospective clinical studies across thousands of cases globally.The 20mg/ml concentration contains the same pharmaceutical-grade GS-441524 as all CureFIP™ injectable formulations. Concentration variation is a manufacturing and clinical precision decision, not a quality distinction. Concentration Selection Guide<table> <tbody> <tr> <th>Concentration</th> <th>Primary Indication</th> </tr> <tr> <td>20mg/ml (this product)</td> <td>Cats under 2.5 kg · Kittens · Precision low-volume dosing</td> </tr> <tr> <td>30mg/ml</td> <td>Cats 2.5–5 kg · Standard FIP cases · First-line treatment</td> </tr> <tr> <td>40mg/ml</td> <td>Cats over 5 kg · High-dose protocols · Resistance · Relapse</td> </tr> <tr> <td>20mg/ml + B12</td> <td>Cats under 2.5 kg with anaemia, neurological symptoms, or appetite loss</td> </tr> </tbody></table> AdministrationAdminister subcutaneously once daily. Dose is calculated in mg of GS-441524 per kg of body weight. The standard treatment duration is 84 days of consecutive daily dosing without interruption. Do not adjust dose without veterinary guidance. Use the dosing calculator to determine the correct volume for your cat's current weight.Treatment response is typically observed within the first 7 days — appetite improvement, reduction in fever, and increased activity are the earliest indicators. If no response is observed within 7 days, contact our clinical support team before discontinuing treatment. Quality and SourcingCureFIP™ injectables are manufactured to pharmaceutical-grade standards with documented API sourcing, concentration verification, and stability testing. Each batch is tested for GS-441524 concentration accuracy before release. We provide full transparency on formulation specifications — contact our team for batch documentation if required for veterinary records. https://video.wixstatic.com/video/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4/1080p/mp4/file.mp4 https://www.curefipeurope.com/product-page/40mg 2026-06-22 https://static.wixstatic.com/media/0bcfb2_c5a99ea6448f49aeabed3d50ff3697d4~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_c180457ac64b406494a6c591378991a5~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_886f657c3aff4365867a44be03c9d326~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_39758857b3804f63a4f1c9f35513bac2~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_5138059f1367434297930c9175e5299d~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_2def33054646443bb8642d84a0690a16~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_ccf0e83507974af79d5b759e7630ecd7~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4f002.jpg/v1/fit/w_50,h_50,q_90/file.jpg Cure FIP Antiviral,【40mg/ml】10ML CureFIP™ GS-441524 Injectable 40mg/ml High-Concentration Antiviral for Large Cats, Severe Cases, Resistance, and Relapse What This Product IsCureFIP™ GS-441524 40mg/ml is the highest-concentration formulation in the CureFIP™ injectable range. It is not a more potent version of the 30mg/ml formulation — the antiviral mechanism and the dose delivered per kg of body weight are identical. The 40mg/ml concentration exists to address a specific clinical problem: delivering an adequate GS-441524 dose in a manageable injection volume when standard concentrations produce volumes that are either excessive or impractical. This formulation serves four primary use cases: large cats whose weight demands high absolute doses, high-dose induction protocols at treatment onset, cases where GS-441524 resistance is suspected and dose escalation is clinically indicated, and relapse cases requiring aggressive retreatment. Why 40mg/ml Is Necessary: The Volume ArgumentFIP treatment dose is calculated in mg of GS-441524 per kg of body weight. For a 6 kg cat at a standard dose of 4 mg/kg, the required GS-441524 per injection is 24 mg. At 30mg/ml, this requires 0.8ml — a manageable volume. At higher dose protocols (6–8 mg/kg), the same cat requires 36–48 mg per injection. At 30mg/ml, that becomes 1.2–1.6ml per injection — approaching the upper limit of comfortable subcutaneous administration. At 40mg/ml, the same doses require 0.9–1.2ml — within comfortable range. The 40mg/ml format does not change what the cat receives. It changes the volume in which it is delivered, reducing injection site stress and improving administration practicality at high dose levels. Indicated CasesLarge adult cats over 5 kg Body weight directly determines GS-441524 dose requirement. Cats above 5 kg — Maine Coons, Ragdolls, Norwegian Forest Cats, and large domestic shorthairs — consistently require doses that produce impractical injection volumes at 30mg/ml, particularly at the upper end of standard dosing ranges. High-dose induction at treatment onset Some clinical protocols employ an elevated GS-441524 dose during the first 2–4 weeks of treatment to achieve rapid reduction in viral load before transitioning to standard maintenance dosing. The 40mg/ml formulation is optimised for this induction phase, keeping injection volumes within tolerable limits at elevated dose levels. Suspected GS-441524 resistance Viral resistance to GS-441524 is documented in FIP treatment literature, particularly in cats that have previously received partial or interrupted treatment courses, or that have relapsed following complete treatment. When standard dosing produces insufficient clinical response, dose escalation is a clinically indicated first step before switching agents. The 40mg/ml format makes escalation to 6–8 mg/kg practical without excessive injection volumes. Relapse cases Cats that relapse following completed treatment — particularly within the first 6 months post-treatment — typically require more aggressive retreatment protocols than first-line cases. The 40mg/ml formulation supports the higher dose ranges clinically indicated in relapse management. Severe acute presentations In severe wet FIP, rapidly progressing neurological FIP, and advanced ocular FIP where the treatment window is narrow, aggressive early dosing is clinically justified. The 40mg/ml format enables high-dose initiation from day one of treatment without volume compromise. This Formulation Is Not the First Choice For<ul> <li>Cats weighing under 5 kg at standard dose ranges — the 30mg/ml formulation provides adequate dosing precision</li> <li>First-line treatment of typical FIP cases in standard-weight cats — 30mg/ml is appropriate and better characterised for this population</li> <li>Cases where systemic complications (anaemia, neurological involvement) are the primary concern — consider the 40mg/ml + B12 formulation</li></ul> Clinical Background and Resistance ConsiderationGS-441524 resistance in FIP treatment has been documented in case reports and small case series, though it remains infrequent in cats completing a full uninterrupted 84-day course at appropriate doses. Resistance risk is highest in cats that received subtherapeutic doses — due to underdosing, treatment interruptions, or low-quality formulations — and in relapse cases. For confirmed or strongly suspected resistance, dose escalation with 40mg/ml is an appropriate first intervention. If escalated monotherapy fails to produce response, transition to dual antiviral therapy with EIDD-1931 (CureFIP™ Dual Antiviral Oral Capsules) — which provides a second, mechanistically distinct antiviral barrier that GS-441524-resistant virus cannot simultaneously overcome. Concentration Selection Guide<table> <tbody> <tr> <th>Concentration</th> <th>Primary Indication</th> </tr> <tr> <td>20mg/ml</td> <td>Cats under 2.5 kg · Kittens · Precision dosing</td> </tr> <tr> <td>30mg/ml</td> <td>Cats 2.5–5 kg · Standard FIP · First-line treatment</td> </tr> <tr> <td>40mg/ml (this product)</td> <td>Cats over 5 kg · High-dose · Severe · Resistance · Relapse</td> </tr> <tr> <td>40mg/ml + B12</td> <td>Same as above with concurrent anaemia or systemic complications</td> </tr> </tbody></table> AdministrationAdminister subcutaneously once daily. Dose is calculated in mg of GS-441524 per kg of body weight — the concentration change does not alter the dose calculation principle. Standard treatment duration is 84 consecutive days. For high-dose induction protocols, follow veterinary guidance on dose reduction schedule after the induction phase. Use the dosing calculator to determine the correct volume for your cat's current weight and target dose. For relapse or resistance cases, contact our clinical support team before beginning retreatment. Our team can advise on appropriate dose selection and whether dual antiviral therapy should be initiated alongside or instead of dose escalation. https://video.wixstatic.com/video/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4/1080p/mp4/file.mp4 https://www.curefipeurope.com/product-page/eidd-1931 2026-05-31 https://static.wixstatic.com/media/458dcb_bd80f11f1e2742fd975ab3e1e682b528~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/458dcb_ccd6cf2da3604a6ca09edf3aa1c2b258~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/458dcb_e36d07b450fc49ed8ec8ac4f3bd8e881~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_579f91718ca44507853203959d3c1f7a~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://www.curefipeurope.com/product-page/pills 2026-07-14 https://static.wixstatic.com/media/0bcfb2_5954c65ec9f941398eda1e55a1fead1a~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_c180457ac64b406494a6c591378991a5~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_39758857b3804f63a4f1c9f35513bac2~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_886f657c3aff4365867a44be03c9d326~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_5138059f1367434297930c9175e5299d~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_2def33054646443bb8642d84a0690a16~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_ccf0e83507974af79d5b759e7630ecd7~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_d2722636df194ac597eaae3186015d68~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_0717b3d167894585afc59ff537df067d~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/458dcb_1bacaf6db8c3419bbf6cf34e7833a525f002.jpg/v1/fit/w_50,h_50,q_90/file.jpg CURE FIP™ Dual Antiviral Oral Capsules CURE FIP™ Dual Antiviral Oral Capsules (GS-441524 + EIDD-1931)Advanced Dual-Action Treatment for Cats with FIP Product DescriptionCURE FIP™ Dual Antiviral Capsules combine two powerful antiviral ingredients — GS-441524 and EIDD-1931 — in a single oral capsule designed to support cats undergoing treatment for Feline Infectious Peritonitis (FIP). Using two antivirals together provides a balanced treatment approach. GS-441524 helps stop the virus from multiplying, while EIDD-1931 works through a different mechanism to further disrupt viral replication. This dual-action strategy helps improve treatment reliability and may reduce the risk of the virus developing resistance to a single medication. By combining both antivirals in carefully balanced amounts, the formula also helps avoid the need for excessively high doses of any one drug, supporting a safer and more controlled treatment plan for your cat. CURE FIP™ Dual Antiviral Capsules are designed to be simple for owners to administer at home, making daily treatment easier and less stressful for both cats and their caregivers. Key Benefits• Dual-antiviral protection – combines GS-441524 and EIDD-1931• Two mechanisms against the virus for a more comprehensive treatment approach• Helps reduce the risk of viral resistance seen with single-drug treatments• Allows balanced dosing without relying on very high amounts of one antiviral• Convenient oral capsules for easy daily administration• Trusted by thousands of cat owners worldwide treating FIP   https://video.wixstatic.com/video/458dcb_1bacaf6db8c3419bbf6cf34e7833a525/1080p/mp4/file.mp4 https://www.curefipeurope.com/product-page/30mg 2026-07-28 https://static.wixstatic.com/media/0bcfb2_271339952c6b4b27bf2398910733560c~mv2.jpg/v1/fit/w_1080,h_1080,q_90/file.jpg https://static.wixstatic.com/media/0bcfb2_c180457ac64b406494a6c591378991a5~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_886f657c3aff4365867a44be03c9d326~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_39758857b3804f63a4f1c9f35513bac2~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_5138059f1367434297930c9175e5299d~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_2def33054646443bb8642d84a0690a16~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/0bcfb2_ccf0e83507974af79d5b759e7630ecd7~mv2.png/v1/fit/w_1080,h_1080,q_90/file.png https://static.wixstatic.com/media/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4f002.jpg/v1/fit/w_50,h_50,q_90/file.jpg CureFIP™ GS-441524 Injectable 30mg/ml CureFIP™ GS-441524 Injectable 30mg/ml The Standard Concentration — CureFIP™'s Most Widely Used FIP Injectable What This Product IsCureFIP™ GS-441524 30mg/ml is the most widely used formulation in the CureFIP™ injectable range. It contains GS-441524 — a nucleoside analogue antiviral — at a concentration optimised for the standard FIP treatment protocol in adult cats weighing 2.5 to 5 kg. It covers all primary FIP presentations without neurological involvement: wet (effusive) form, dry (non-effusive) form, and ocular form. The 30mg/ml concentration is not the standard because it is the middle option in our range. It is the standard because it produces the most clinically practical injection volume for the weight range that represents the majority of FIP cases — adult domestic cats between 2.5 and 5 kg. Why 30mg/ml Is the Clinical DefaultFIP treatment dosing is determined by mg of GS-441524 per kg of body weight. Across the 2.5–5 kg adult cat weight range, the 30mg/ml concentration simultaneously satisfies three requirements that determine clinical practicality:The injection volume is large enough to be measured accurately with a standard syringe — eliminating the measurement error risk associated with the very small volumes produced by 40mg/ml in this weight range. The injection volume is small enough to be administered comfortably in a single subcutaneous injection — avoiding the excessive volumes produced by 20mg/ml in this weight range.The concentration is consistent enough to support precise daily dose adjustment as a cat's weight changes during treatment — which is common as cats in recovery gain condition.This is why 30mg/ml accounts for the majority of CureFIP™ injectable treatment courses across all markets. Indicated CasesThis formulation is appropriate for:<ul> <li>Adult cats weighing 2.5 to 5 kg at treatment initiation</li> <li>Wet (effusive) FIP — abdominal effusion, pleural effusion</li> <li>Dry (non-effusive) FIP — granulomatous lesions, organ involvement</li> <li>Ocular FIP — uveitis, aqueous flare, chorioretinitis</li> <li>First-line treatment following new FIP diagnosis</li> <li>Cats selecting GS-441524 monotherapy rather than dual antiviral protocol</li></ul> This Formulation Is Not the First Choice For<ul> <li>Cats weighing under 2.5 kg — the 20mg/ml formulation is indicated for dosing precision</li> <li>Cats weighing over 5 kg — the 40mg/ml formulation avoids excessive injection volumes</li> <li>Cats presenting with neurological FIP — consider dual antiviral therapy with EIDD-1931 (CureFIP™ Dual Antiviral Oral Capsules) or the 30mg/ml + B12 formulation for additional systemic support</li> <li>Cases with confirmed GS-441524 resistance or relapse — the 40mg/ml formulation and dual antiviral protocol are indicated</li></ul> Clinical BackgroundGS-441524 is a nucleoside analogue antiviral that inhibits feline coronavirus (FCoV/FIPV) replication. Following cellular uptake and phosphorylation to its active triphosphate metabolite (GS-443902), it acts as a substrate for the viral RNA-dependent RNA polymerase (RdRp). The 1'-cyano substitution causes steric clash following incorporation into nascent RNA chains, producing delayed chain termination and halting viral RNA synthesis. First described as effective against FIP in Pedersen et al. (2019, Nature), GS-441524 has since been evaluated in multiple prospective randomised controlled trials and retrospective cohort studies. Published remission rates in completed treatment cohorts consistently range from 80 to 94% across wet, dry, and ocular presentations. The 30mg/ml concentration has the longest clinical track record of any concentration in the CureFIP™ range due to its position as the standard treatment formulation. Concentration Selection Guide<table> <tbody> <tr> <th>Concentration</th> <th>Primary Indication</th> </tr> <tr> <td>20mg/ml</td> <td>Cats under 2.5 kg · Kittens · Precision low-volume dosing</td> </tr> <tr> <td>30mg/ml (this product)</td> <td>Cats 2.5–5 kg · All standard FIP presentations · First-line</td> </tr> <tr> <td>40mg/ml</td> <td>Cats over 5 kg · High-dose protocols · Resistance · Relapse</td> </tr> <tr> <td>30mg/ml + B12</td> <td>Cats 2.5–5 kg with anaemia, neurological symptoms, or appetite loss</td> </tr> </tbody></table> Dual Antiviral OptionIf your cat has previously been treated with GS-441524 and relapsed, or if your veterinarian suspects early resistance, consider CureFIP™ Dual Antiviral Oral Capsules (GS-441524 + EIDD-1931). Combining two antivirals with distinct mechanisms of action — RdRp chain termination and lethal mutagenesis — creates a dual barrier against viral resistance that monotherapy cannot provide. AdministrationAdminister subcutaneously once daily. Dose is calculated in mg of GS-441524 per kg of body weight. Standard treatment duration is 84 consecutive days without interruption. Weigh your cat weekly and recalculate dose if weight changes by more than 10%. Use the dosing calculator to determine the correct injection volume for your cat's current weight.Most cats show observable treatment response within the first 7 days — appetite improvement and fever reduction are the earliest indicators. Blood parameter normalisation typically follows over weeks 2–4. If no clinical response is observed within 7 days, contact our clinical support team. https://video.wixstatic.com/video/458dcb_afdc1c598f6f419faf8f2b9e6182d0f4/1080p/mp4/file.mp4